Duality Biotherapeutics, Inc. Stock OTC Markets
Stocks
DYBT.Y
US2639081056
Pharmaceuticals
OTC Markets Traded| Market Cap | 18.29B 2.7B 2.37B 2.21B 2.02B 3.8B 260B 3.86B 26.19B 10.23B 128B 10.14B 9.92B 442B | P/E 2026 * |
-42.2x | P/E 2027 * | -37.3x |
|---|---|---|---|---|---|
| Enterprise Value | 18.5B 2.73B 2.4B 2.23B 2.05B 3.85B 263B 3.91B 26.51B 10.36B 129B 10.26B 10.04B 447B | EV / Sales 2026 * |
11.5x | EV / Sales 2027 * | 13.3x |
| Free-Float |
74.74% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhong Yuan Zhu
CEO | Chief Executive Officer | 56 | 2019-07-02 |
Shao Ren Zhang
DFI | Director of Finance/CFO | 40 | 2026-03-22 |
Mu Wen Hua
CTO | Chief Tech/Sci/R&D Officer | - | 2025-04-06 |
| Director | Title | Age | Since |
|---|---|---|---|
Zhong Yuan Zhu
CHM | Chairman | 56 | 2019-07-02 |
Hai Qing Hua
BRD | Director/Board Member | 45 | 2026-03-22 |
Shao Ren Zhang
BRD | Director/Board Member | 40 | 2021-04-22 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 2.71B | |
| +1.20% | -2.62% | +16.70% | -9.38% | 66.32B | |
| +1.23% | +2.80% | +37.51% | +202.14% | 52.6B | |
| +10.08% | +51.80% | +51.80% | +51.80% | 43.27B | |
| -1.32% | -6.34% | -56.98% | -57.24% | 38.64B | |
| +0.86% | -1.95% | +52.33% | -27.08% | 29.62B | |
| +1.00% | +0.45% | +67.09% | +85.60% | 23.31B | |
| -4.85% | -12.28% | +59.45% | -55.91% | 22.62B | |
| -1.21% | -4.51% | +2.22% | +174.24% | 20.22B | |
| -0.22% | -0.95% | +61.97% | +123.78% | 16.29B | |
| Average | +0.68% | -1.33% | +32.45% | +54.22% | 34.77B | |
| Weighted average by Cap. | +1.41% | -0.65% | +27.59% | +49.56% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.6B 237M 208M 193M 177M 333M 22.8B 339M 2.3B 897M 11.21B 889M 870M 38.76B | 1.43B 211M 185M 172M 158M 297M 20.3B 301M 2.04B 799M 9.98B 791M 774M 34.5B |
| Net income | -329M -48.54M -42.63M -39.65M -36.38M -68.36M -4.67B -69.41M -471M -184M -2.3B -182M -178M -7.95B | -440M -64.92M -57.02M -53.02M -48.66M -91.42M -6.25B -92.83M -630M -246M -3.07B -244M -238M -10.63B |
| Net Debt | 219M 32.29M 28.36M 26.37M 24.2M 45.47M 3.11B 46.17M 313M 122M 1.53B 121M 119M 5.29B | 689M 102M 89.32M 83.06M 76.22M 143M 9.79B 145M 986M 385M 4.81B 382M 374M 16.65B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
